Evonik is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The facility will increase Evonik's development and manufacturing capacity, helping pharmaceutical and biotech customers bring lipid-based pharmaceutical products including vaccines, therapeutics, and other advanced medicines from development through commercial scale. Evonik's total investment of over 150 million CAD (93 million EUR) in Vancouver is supported by the Canadian federal government's Strategic Response Fund with up to 68 million CAD (around 42 million EUR). Drug product production is planned to begin at the end of 2029.
"Lipid-based drug delivery technologies are already enabling the next generation of medicines. With the support of the Canadian federal government, this investment builds on our long-standing expertise in the field, enabling the development and commercialization of more life-changing therapies," said Lauren Kjeldsen, member of Evonik's Executive Board and COO for the Custom Solutions segment at Evonik.
The project will expand Evonik's existing manufacturing capabilities through the establishment of a modern GMP facility with more than three times the manufacturing capacity of the current facility for advanced pharmaceutical products. The new facility will also significantly advance quality control (QC) and microbiological testing capabilities, improving efficiency and supporting the timely release of products for clinical use.
"The Vancouver region is a vibrant hub for life sciences innovation, and Evonik's Health Care business is proud to be growing within and with this ecosystem. This investment strengthens both our regional presence and our global network for lipid-based drug delivery," said Guido Skudlarek, head of Evonik's Health Care business line.